General Announcement::Glenmark Pharmaceuticals receives ANDA approval for Lacosamide Tablets USP

Issuer & Securities

Issuer/ Manager
GLENMARK PHARMACEUTICALS LIMITED
Securities
GLENMARK PHARM US$170M2%220628 - XS1426780125 - 4G8B
Stapled Security
No

Announcement Details

Announcement Title
General Announcement
Date &Time of Broadcast
21-Mar-2022 13:18:53
Status
New
Announcement Sub Title
Glenmark Pharmaceuticals receives ANDA approval for Lacosamide Tablets USP
Announcement Reference
SG220321OTHR44PJ
Submitted By (Co./ Ind. Name)
Glenmark Pharmaceuticals Limited
Designation
Company Secretary & Compliance Officer
Effective Date and Time of the event
21/03/2022 00:00:00
Description (Please provide a detailed description of the event in the box below)
Glenmark Pharmaceuticals receives ANDA approval for Lacosamide Tablets USP, 50 mg, 100 mg, 150 mg and 200 mg.

Attachments

SGX_PR_21032022.pdf
Total size =255K